Shilpa Medicare Limited
SHILPAMED · NSE · Healthcare
With a 20% margin of safety, our buy-below price is ₹405.4.
Piotroski F-score 7/9 — quality of earnings & balance sheet.
Investability checklist
- ✕ROE above 15%9.8%
- ✓Low debt (D/E < 0.5)0.25x
- ✕Positive free cash flow
- ✓Revenue growth > 10%32%
- ✓Earnings growing645%
- ✓Net margin ≥ 10%15.8%
- ✕Current ratio > 1.51.31
- ✕Below our fair value
- ✕Margin of safety ≥ 20%
- ✓Above 200-day average
- ✓Above 50-day average
- –Positive 1-year return
- ✓Altman Z in safe zoneZ 6.71
- ✓Piotroski ≥ 77/9
1-year price
EOD · 2026-06-16Our scores
Durability rewards strong, low-debt, profitable businesses; Valuation rewards stocks cheap vs their sector; Momentum rewards strong price trends.
Quarterly results
Annual financials
Shareholding
Promoter holding via insider stake; institutional via reported holdings.
Analyst views
Key fundamentals
SWOT snapshot
Strengths
- •Lightly leveraged balance sheet.
- •Healthy profit margin (15.8%).
- •Trading near its 52-week high.
- •Financially solid — Altman Z 6.71.
- •High Piotroski quality score (7/9).
Opportunities
- •Earnings growing (645% YoY).
- •Revenue growing (32% YoY).
About Shilpa Medicare Limited
Shilpa Medicare Limited, together with its subsidiaries, manufactures and sells active pharmaceutical ingredients (APIs), finished dosage formulations, biosimilars, and contract development and manufacturing organisation in India, the United States, Europe, and internationally. The company offers various oncology and non-oncology APIs, such as anastrozole, acebrophylline, ambroxol hydrochloride, axitinib, azacitidine, abiraterone acetate, bendamustine HCL monohydrate, bicalut
More in Healthcare
Our verdict, fair value, financial-health and checklist are StocksWizard's own estimates, computed from public end-of-day data using standard models (DCF, relative valuation, Altman Z, Piotroski). For information only — not investment advice or a recommendation. Verify independently before investing.